⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 15, 2024Open Access

Supplementary Figure S5 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Aina Oliver‐Caldés Marta Español‐Rego Aintzane Zabaleta Verónica González‐Calle Sergio Navarro‐Velázquez Susana Inogés Ascensión López-Dı́az de Cerio Valentín Cabañas Nieves López‐Muñoz Paula Rodríguez‐Otero Juan Luis Reguera David F. Moreno Núria Martínez‐Cibrián Lucía López‐Corral Lorena Pérez-Amill Beatriz Martín-Antonio Laura Rosiñol Joan Cid Natalia Tovar Joaquín Sáez‐Peñataro Miriam López-Parra Eulàlia Olesti Elena Guillén Sara Varea Luis Gerardo Rodríguez‐Lobato Anthony M. Battram Marta Sonia González Andrés Sánchez‐Salinas Europa Azucena González‐Navarro Valentín Ortiz‐Maldonado Julio Delgado Felipe Prósper Manel Juan Joaquín Martínez‐López José M. Moraleda María‐Victoria Mateos Álvaro Urbano-Ispizúa Bruno Paiva Mariona Pascal Carlos Fernández de Larrea

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure 5. ARI0002h persistence according to baseline tumor burden measured as proportion of bone marrow plasma cells and soluble BCMA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oliver‐Caldés et al. (2024) studied this question.

synapsesocial.com/papers/68e6a13db6db643587624da4 https://doi.org/10.1158/1078-0432.25826711.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S5 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
2Supplementary Figure S4 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
3Supplementary Figure S4 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
4Supplementary Figure S3 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
5Supplementary Figure S3 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024

More related papers

Supplementary Figure S6 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
Supplementary Figure S6 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
Supplementary Figure S7 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024